
Efficacy sets the starting point, but performance status, comorbidities, patient priorities, and distinct adverse event patterns determine which first-line regimen a patient actually receives.

Efficacy sets the starting point, but performance status, comorbidities, patient priorities, and distinct adverse event patterns determine which first-line regimen a patient actually receives.

Behind every case of bronchiectasis is a self-perpetuating cycle of cough, breathlessness, and infection that leaves many patients unable to return to their prior baseline health.

Bronchiectasis pathophysiology looks less linear and more dynamic than once believed, and its true prevalence appears far higher than commonly assumed across the adult population.

MS prevalence continues to rise and the demographic profile is broader than long assumed. The panel identifies progressive biology as the largest remaining unmet need in the disease.

A rare EGFR subtype demands comprehensive molecular testing at diagnosis, and the first-line standard has shifted from chemotherapy alone to a targeted combination with survival benefit.

Early transplant referral, MRD-guided sequencing, and a candid accounting of intensive chemotherapy's costs shape how clinicians move older and high-risk patients toward potential cure.

From intensive induction with targeted add-ons to lower-intensity venetoclax-based combinations, frontline AML therapy now branches by mutation, fitness, and the realistic prospect of cure without transplant.

Fewer than two-thirds of patients prescribed augmentation begin infusions, and half of starters miss doses. Structured education lifts adherence sharply, while plasma supply and partial coverage expose the limits of current therapy.

Two pivotal trials, built on different designs and chemotherapy backbones, delivered comparable, if modest, survival gains in extensive-stage disease, giving clinicians flexibility while leaving progression-free survival largely unmoved.

Extensive-stage small cell lung cancer resisted immunotherapy's promise longer than its non-small cell counterpart, but a small, durable subset of long-term survivors justified testing checkpoint inhibitors against a historically difficult tumor.

Weekly dosing produces high early levels and a falling trough. Panelists explain how they balance exacerbations, travel, and infusion access, and why they discourage routine level monitoring once therapy begins.

Three subtle physical findings can signal that vitiligo is about to spread. Dr. Hamzavi outlines the warning signs of active disease and the practical scoring approach he uses instead of research metrics.

Seven approved biologics now target distinct points in the inflammatory cascade, giving clinicians genuine options, even for patients with low eosinophil levels.

Every dose is another opportunity to miss one. Real-world evidence indicates that longer biologic dosing intervals are associated with higher persistence and fewer treatment gaps.

A careful physical exam, targeted laboratory testing, and a low threshold for biopsy remain the foundation of vitiligo diagnosis. Dr. Desai details the workup he uses with every new patient.

A diagnostic delay of seven to ten years leaves patients carrying myths of poor hygiene and infection. Dr. Lev-Tov argues that naming the disease is itself an intervention.

Diagnosing HS is simpler than many clinicians assume. A three-part framework and one screening question help clinicians recognize the disease early, so awareness rather than technique becomes the real challenge.

Performance status, comorbidity indices, and geriatric assessment frame what a patient can tolerate, while insurance, health literacy, and caregiver support often determine what care is actually feasible.

Being able to tolerate intensive chemotherapy is not the same as benefiting from it. The panel weighs psychosocial realities and candid case outcomes in older patients with AML.

Even with consolidation immunotherapy, most limited-stage patients still recur, a reminder that biomarker-driven approaches, earlier detection, and next-generation agents remain essential to moving survival further.

The 11 micromolar target was built on epidemiologic reasoning rather than a normal range. Pending trials of higher doses and longer-acting agents may show whether raising levels further improves outcomes.

Logistics, not efficacy, often decide who completes limited-stage treatment. Distance from infusion centers, caregiver support, and clinic workflows can matter as much as the medicine itself in determining outcomes.

Looking ahead, Dr. Citrome weighs how payers should structure formulary access today against the long-term evidence still missing on treatment duration and relapse risk.

Four plasma-derived products deliver the same purified protein and appear clinically interchangeable. Differences in formulation, administration, and coverage design shape which product a patient actually receives.

Adherence depends on clear explanation, reliable inhaler technique, and affordable medication, and gaps in any one of these can quietly erode the benefit of an effective treatment plan.

Vitiligo begins with oxidative stress and ends with CD8-positive T cells destroying melanocytes that cannot easily regenerate. Dr. Hamzavi maps the autoimmune cascade and the disease associations clinicians should watch for.

Vitiligo affects up to two percent of the population worldwide, yet payers and patients alike still misread it as cosmetic. Dr. Desai explains the autoimmune biology, systemic comorbidities, and diagnostic pitfalls that argue otherwise.

Whether the goal is remission or simply fewer exacerbations depends heavily on the population served, and repeated steroid bursts quickly accumulate into lasting harm.

Despite a clear survival benefit, a meaningful share of eligible patients never receive consolidation immunotherapy after chemoradiation, exposing a gap between what trial data supports and what real-world practice actually delivers.

The ADRIATIC trial reshaped limited-stage treatment, extending median survival by nearly two years with consolidation immunotherapy, a shift so significant that adherence, not efficacy, is now the field's central clinical challenge.